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Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment
Summary: Enzyme replacement therapy with recombinant ␣-galactosidase A clears microvascular deposits of globotriaosylceramide in biopsies of kidney, skin, and heart of most Fabry patients. Clinically, it could be demonstrated that enzyme replacement therapy reduces left ventricular hypertrophy and improves regional myocardial function in patients with Fabry cardiomyopathy during short-term treatment. Whether enzyme replacement therapy is effective in all stages of Fabry cardiomyopathy during long-term follow-up is unknown. The present study shows that a baseline assessment of cardiac morphology and function before the start of enzyme replacement therapy is necessary. Thus, knowledge of the presence or absence of myocardial fibrosis (which is typical for a late stage of this disease) is crucial with respect to treatment expectations. Myocardial fibrosis can be visualized directly with the MRI late-enhancement technique. In addition, the functional consequences of fibrosis can be quantified by ultrasonic strain-rate imaging. Only Fabry patients with no fibrosis before enzyme replacement therapy show a sustained improvement in regional myocardial function and exercise capacity in the long term. Thus, in Fabry disease, early is probably superior to late treatment to improve cardiac morphology, function, and exercise capacity.
Conclusions: These data suggest that treatment of Fabry cardiomyopathy with recombinant ␣-galactosidase A should best be started before myocardial fibrosis has developed to achieve long-term improvement in myocardial morphology and function and exercise capacity. 1
A Novel Role for Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) in the Development of Cardiac Dysfunction and Failure
Summary: Cardiomyopathy and heart failure remain the only cardiovascular diseases in which the incidence and mortality continue to rise. Despite intensive investigation, the mechanisms underlying the pathophysiology of heart failure and the progression of cardiac dysfunction remain poorly understood. In the present report, we identify a novel cytokine, TWEAK, and its cellular receptor Fn14 as important mediators of cardiac dysfunction and cardiomyopathy. Augmenting circulating TWEAK levels in mice through genetic approaches resulted in the development of dilated cardiomyopathy, with subsequent cardiac dysfunction and early mortality, a process dependent on the Fn14 cellular receptor. Moreover, we found that circulating TWEAK levels are elevated in patients with idiopathic dilated cardiomyopathy relative to other forms of heart disease and normal control subjects. Taken together, our data suggest that TWEAK/Fn14 may play an important role in the pathogenesis of cardiomyopathy.
Conclusions: Our data suggest that TWEAK/Fn14 may be important in regulating myocardial structural remodeling and function and may play a role in the pathogenesis of dilated cardiomyopathy. 2
The Relationship of Right-and Left-Sided Filling Pressures in Patients With Heart Failure and a Preserved Ejection Fraction
Summary: Assessment of the left ventricular filling pressure in patients with heart failure (HF) often includes examination of the jugular veins to estimate the central venous pressure (right ventricular filling pressure). This approach has been shown to be useful in patients with systolic HF because right and left ventricular filling pressures often mirror each other in this setting. However, it is not known whether this relationship exists in patients with HF and a preserved left ventricular ejection fraction. In this study, 11 subjects with HF with preserved ejection fraction underwent right heart catheterization at rest and under loading conditions manipulated by lower body negative pressure or head-up tilt and by saline infusion. Right atrial pressure (RAP) was classified as elevated when Ն10 mm Hg, and pulmonary capillary wedge pressure (PCWP) when Ն22 mm Hg. If both the RAP and the PCWP were elevated or both not elevated, the RAP and PCWP were classified as concordant; otherwise, they were classified as discordant. Among 66 paired measurements of RAP and PCWP, 44 (67%) had a low RAP and PCWP and 8 (12%) a high RAP and PCWP, yielding a concordance rate of 79%. The correlation coefficient of RAP and PCWP for the overall cohort was rϭ0.86 (PϽ0.0001). We conclude that rightsided filling pressures often reflect left-sided filling pressures in HF with preserved ejection fraction, supporting the role of estimation of jugular venous pressure to assess volume status in this condition.
Conclusions: Right-sided filling pressures often reflect left-sided filling pressures in heart failure with preserved ejection fraction, supporting the role of estimation of jugular venous pressure to assess volume status in this condition. 3 
Mechanisms Underlying Improvements in Ejection Fraction With Carvedilol in Heart Failure
reduction being correlated with changes in ejection fraction (EF). However, the relative contributions of other factors affected by ␤-blockers to increases in EF, including an increase in contractility, a reduction in afterload resistance and reverse remodeling (hypertrophy regression and decreased end-diastolic volume) of the dilated left ventricle in addition to heart rate reduction are not known. In this study, 29 subjects with systolic heart failure underwent serial measures of chamber and vascular properties using 3-dimensional echocardiography and blood pressures by sphygmomanometry at baseline, 2 weeks, 2, 6, and 12 months after initiation of carvedilol. The increase in EF (7 percentage points) after 6 months of therapy correlated with increased contractility, decreased heart rate (HR), and decreased total peripheral resistance and among those patients whose EF increased at least 5 points, Ϸ60% of the increase was due to HR reduction, Ϸ30% was due to increased contractility and Ͻ20% was due to the decrease in total peripheral resistance. These data suggest that mechanistically, HR reduction is a major factor contributing to the increase in EF with carvedilol therapy. This suggests that efforts to find alternate means of reducing HR can be fruitful, particularly for patients intolerant to ␤-blocker therapy or for those whom HR does not decrease adequately in response to ␤-blockers.
Conclusions: Decreased HR, improved chamber contractility and afterload reduction each contributed significantly to improved EF with carvedilol. 4
Endothelial Cell-Derived Endothelin-1 Promotes Cardiac Fibrosis in Diabetic Hearts Through Stimulation of Endothelial-to-Mesenchymal Transition
Summary: Despite optimal treatment with current standard therapy, the high risk of heart failure and major cardiovascular events remains an unresolved problem for patients with diabetic cardiomyopathy. Thus, a better understanding of the underlying mechanisms and additional therapeutic strategies is needed. A persistently high plasma endothelin-1 (ET-1) level in diabetic patients is associated with the development of cardiac fibrosis. Considering the unfavorable results from clinical trials using ET-1 receptor blockade in heart failure patients-in contrast to its successful application in pulmonary arterial hypertension patients-we conducted more detailed investigation into the role of specific cell-derived ET-1. The importance of endothelial cells as a major source of ET-1 and the contribution of endothelial dysfunction in the natural history of diabetes cardiovascular complications led us to use endothelial cell-specific ET-1 knockout mice that we generated previously. In a type 1 diabetes model, we made the novel observations that diabetes mellitus-induced cardiac fibrosis is associated with the emergence of fibroblasts from endothelial cells and that this so-called endothelial-tomesenchymal transition is stimulated by endothelial cell-derived ET-1. This cardiac fibrosis, along with ET-1-induced ultrastructural abnormalities, oxidative stress, and impairment of cardiac microvascularization, contributes to the acceleration of heart failure, which is ameliorated in mice lacking ET-1 in endothelial cells. We therefore suggest that targeting endothelial cell-derived ET-1 might be beneficial in the prevention of diabetic cardiomyopathy.
Conclusions:
These results provide new insights suggesting that diabetes mellitus-induced cardiac fibrosis is associated with the emergence of fibroblasts from endothelial cells and that this endothelial-to-mesenchymal transition process is stimulated by ET-1. Targeting endothelial cell-derived ET-1 might be beneficial in the prevention of diabetic cardiomyopathy. 5
Peripartum Cardiomyopathy as a Part of Familial Dilated Cardiomyopathy
Summary: Anecdotal cases with familial clustering of peripartum cardiomyopathy (PPCM) or joint occurrence of PPCM and idio-pathic dilated cardiomyopathy (DCM) within families have been reported. We performed the first systematic study of the relation between PPCM and familial DCM. In a substantial number of DCM families (5/90), cases of PPCM were found, and more important, previously undiagnosed cases of DCM were identified in all 3 families of PPCM patients who did not show a full recovery. Moreover, our results support the genetic nature of the disease in 1 DCM family with PPCM: We identified a mutation in the gene encoding cardiac troponin C (TNNC1). We therefore conclude that PPCM can be a manifestation of familial DCM. Obviously, further research is needed to confirm these observations in a larger series of patients. However, our findings already have several clinical implications and may change clinical practice and thinking about PPCM. Because PPCM can be the first manifestation of familial DCM, we recommend presymptomatic cardiological screening for covert DCM in first-degree family members of PPCM patients without recovery of left ventricular function and dimensions. Second, cardiological screening during pregnancy should be considered for healthy women (ie, without proven previous signs of DCM) who are first-degree family members of familial DCM patients and this should be extended into the puerperium.
Conclusions:
Our findings strongly suggest that a subset of PPCM is an initial manifestation of familial DCM. This may have important implications for cardiological screening in such families. 6
Overexpression of Catalase Targeted to Mitochondria Attenuates Murine Cardiac Aging
Summary: Old age is a major risk factor for cardiovascular disease because it prolongs exposure to hypertension, diabetes, hypercholesterolemia, and other cardiovascular risks. However, intrinsic cardiac aging, the slowly progressive structural changes and functional declines with age, also makes the heart more susceptible to stress and contributes to increased risk of cardiovascular mortality and morbidity in the elderly. Using echocardiography, we showed that cardiac aging in mice recapitulates human cardiac aging as documented by prior epidemiological studies: age-dependent increases in left ventricular mass index and diastolic dysfunction and worsening myocardial performance index. Cardiac aging in the mouse is accompanied by increases in mitochondrial protein oxidation, DNA deletions, mitochondrial biogenesis, and ventricular fibrosis, as well as decreased cardiac SERCA2 and activation of the calcineurin-nuclear factor of activated T-cell pathway. Although mitochondrial reactive oxygen species have been proposed as a cause of aging, their role in cardiac aging is unclear. We have previously shown that overexpression of catalase targeted to mitochondria (mCAT) prolongs the murine median lifespan by 17% to 21%. In this study, we demonstrated that all of the age-related changes were significantly attenuated in mCAT mice. Survival analysis showed that echocardiographic parameters are a significant predictor of mortality in mice, even in the absence of hypertension, diabetes, or hypercholesterolemia. This study emphasizes the critical role of mitochondrial reactive oxygen species in cardiac aging and the impact of cardiac aging on survival. These findings also suggest that mitochondria-targeted antioxidants may have a role in treating or preventing reactive oxygen speciesrelated cardiovascular diseases, despite the disappointing results of clinical trials using nontargeted antioxidants.
Conclusions: This study shows that cardiac aging in the mouse closely recapitulates human aging and demonstrates the critical role of mitochondrial reactive oxygen species in cardiac aging and the impact of cardiac aging on survival. These findings also support the potential application of mitochondrial antioxidants in reactive oxygen species-related cardiovascular diseases. 7 formation and subsequent cardiac remodeling characterized by hypertrophy of noninfarct myocardium, left ventricular dilatation, and heart failure. Despite current available treatments, the outcome of MI remains poor. Stem cell factor (SCF) has been shown to promote survival and mobilization of bone marrow stem cells and endothelial progenitor cells. The present study investigated the effects of cardiomyocyte-specific overexpression of the membraneassociated isoform of human SCF (hSCF) on cardiac function after MI. We hypothesized that inducible cardiomyocyte-specific overexpression of membrane-associated hSCF improves cardiac repair, myocardial function, and survival after MI. To test this hypothesis, we generated a novel transgenic mouse that overexpresses membrane-associated hSCF in cardiomyocytes under the control of a Tet-off system. We demonstrated that cardiomyocyte-specific hSCF overexpression increased stem cell and endothelial progenitor cell retention in the infarct myocardium, promoted myocardial angiogenesis, increased capillary density, decreased myocardial apoptosis, and reduced left ventricular hypertrophy after MI. These beneficial effects led to significant improvements in cardiac function and survival in hSCF-overexpressing mice after MI and are likely due to the enhanced recruitment of endothelial progenitor cells to the infarct myocardium and improved cardiac repair. Our study suggests that hSCF may have therapeutic potential in the treatment of heart failure after MI.
Conclusions:
Cardiomyocyte-specific overexpression of hSCF improves myocardial function and survival after MI. These beneficial effects of hSCF may result from increases in endothelial progenitor cell recruitment and neovascularization and decreases in myocardial apoptosis and cardiac remodeling. 8
Mechanisms of Enhanced ␤-Adrenergic Reserve From Cardiac Resynchronization Therapy
Summary: Cardiac resynchronization therapy (CRT) is an effective treatment for patients with heart failure and dyssynchrony caused by conduction delay and is to date the only therapy that can both in the short-term and long-term improve chamber systolic function and yet reduce long-term mortality. The chamber mechanical impact of CRT is well documented and occurs rapidly. However, more long-term influences on both myocyte function and adrenergic modulation that may underlie sustained benefits are largely unknown. To address this, we developed an experimental canine model of dyssynchronous heart failure (tachypacing with a left bundle-branch block) with or without subsequent resynchronization (biventricular tachypacing, CRT). Both models display global heart failure, although CRT did improve systolic function as observed in humans. Here, we show marked global reductions in both resting and ␤-adrenergic-stimulated myocyte function and whole-cell calcium handling in dyssynchronous heart failure and demonstrate that both were markedly improved (␤-adrenergic reserve to nearly normal levels) by CRT. Changes involved calcium homeostasis, increased adrenergic receptor (␤ 1 ) density and adenylate cyclase activity, and novel suppression of inhibitory G-protein signaling. Accompanying this adrenergic upregulation was a decline in myocardial catecholamines from the higher levels observed in dyssynchronous heart failure hearts. Thus, CRT effectively restored a more normal balance of greater cellular adrenergic responsiveness with reduced chronic sympathetic stimulation. This may play an important role in the long-term efficacy of CRT on clinical symptoms and survival and its interaction with concurrent pharmacological neuroblockade treatment.
Conclusions: CRT improves rest and ␤-adrenergic-stimulated myocyte function and calcium handling, upregulating ␤ 1 receptors and adenylate cyclase activity and suppressing G i -coupled signaling associated with novel RGS upregulation. The result is greater rest and sympathetic reserve despite reduced myocardial neurostimulation as components underlying its net benefit. 9
Patient Characteristics and Cell Source Determine the Number of Isolated Human Cardiac Progenitor Cells
Summary: The isolation and expansion of autologous human cardiac progenitor cells may offer new therapies for myocardial regeneration and repair. The present study shows that human cardiac progenitor cells can be obtained from small, clinically relevant myocardial specimens that could be collected during any cardiac surgery or percutaneous myocardial biopsy. Furthermore, these cells can be isolated from a wide range of patients, including young and old patients, those with various comorbidities such as hypertension and diabetes mellitus, and those with diverse types and severity of heart disease. Our study suggests that the best source for cardiac progenitor cells is the right atrium and that these cells are more abundant in women. Our findings could enhance the development of novel approaches in regenerative cardiovascular medicine. These isolated cells could be expanded in vitro, thereby providing a large number of cells for therapeutic applications. Alternatively, if these progenitor cells could be stimulated and activated in situ, with certain growth factors or small molecules, they could provide a tool for myocardial regeneration and the treatment of patients with heart disease.
Conclusion:
Our results show that the right atrium is the best source for c-kit ϩ and Islet-1 progenitors, with higher percentages of c-kit ϩ cells being produced by women. 10
Cardioprotective and Antiapoptotic Effects of Heme Oxygenase-1 in the Failing Heart
Summary: Heme oxygenase-1 (HO-1), which degrades heme to biliverdin, ferrous iron, and carbon monoxide (CO), is rapidly inducible and cardioprotective during acute stress. However, its pathophysiological role in chronic heart failure (HF) is unknown. Using myocyte-restricted HO-1 transgenic mice, we evaluated whether HO-1 upregulation in the failing heart is a beneficial adaptation that alleviates pathological remodeling. Nontransgenic and HO-1 transgenic mice underwent either sham operation or permanent left coronary ligation to induce HF. After 4 weeks, compared with nontransgenic mice with HF, HO-1 transgenic mice with HF exhibited improved postinfarction survival and significantly less left ventricular dilatation and dysfunction, cardiac hypertrophy, fibrosis, and oxidative stress, together with improved tissue neovascularization and reduced myocardial p53 expression and apoptosis. In isolated mitochondria, mitochondrial permeability transition was inhibited by HO-1 in a CO-dependent manner and was recapitulated by the CO donor tricarbonylchloro(glycinato)ruthenium(II) (CORM-3). HO-1-derived CO also prevented H 2 O 2 -induced cardiomyocyte apoptosis and cell death. Finally, sustained in vivo treatment with CORM-3 alleviated postinfarction left ventricular remodeling, p53 expression, and apoptosis in wild-type mice. Our results establish that sustained HO-1 upregulation in HF is an important beneficial adaptation that serves to counteract detrimental left ventricular remodeling via antioxidant, antihypertrophic, antifibrotic, and proangiogenic effects. We have also identified an in vivo antiapoptotic action of HO-1 in the failing heart that is related, at least in part, to CO-mediated stabilization of mitochondrial pore opening. Therefore, augmentation of HO-1 or its product, CO, should be explored as a therapeutic approach to limit pathological left ventricular remodeling and myocyte loss in HF.
Conclusions: HO-1 induction in the failing heart is an important cardioprotective adaptation that opposes pathological left ventricular remodeling, and this effect is mediated, at least in part, by COdependent inhibition of mitochondrial permeability transition and apoptosis. Augmentation of HO-1 or its product, CO, may represent a novel therapeutic strategy for ameliorating HF. 11
Dyssynchrony Indices to Predict Response to Cardiac Resynchronization Therapy: A Comprehensive Prospective Single-Center Study
Summary: Multiple small retrospective studies suggested that various echocardiographic dyssynchrony indices have high sensitivity and specificity for identifying patients with a favorable response to cardiac resynchronization therapy (CRT). However, the multicenter prospective Predictors of Response to CRT (PROSPECT) trial was not able to identify any echocardiographic dyssynchrony parameter that added significant incremental value to the current simple QRS duration and clinical selection criteria for CRT. That study was criticized on the basis of its multicenter format and low reproducibility of many of the studied indices. In the current single-center study, 131 patients with wide QRS and left ventricular ejection fraction Ͻ35% had 6-month follow-up after CRT implantation. Fourteen dyssynchrony indices were evaluated for prediction of reverse remodeling (end-systolic volume reduction Ն15%). Overall, only indices using M-mode, tissue Doppler strain, and total isovolumic time had a receiver operating characteristic area under the curve greater than the line of no information, but none of these were strongly predictive of reverse remodeling. Thus, this prospective single-center study confirmed the PROSPECT trial's conclusion and does not support a routine use of any echocardiographic dyssynchrony index to select patients for CRT. Echocardiographic selection of patients may in fact deny this potentially effective therapy to patients who could benefit from CRT. Future investigations should focus on further characterizing the clinical and laboratory features of the patients who do not respond to CRT.
Conclusions: These findings are consistent with the Predictors of Response to CRT study and do not support use of these dyssynchrony indices to guide use of CRT. 12
Cardio-Renal Effects of the A1 Adenosine Receptor Antagonist SLV320 in Patients With Heart Failure
Summary: Heart failure (HF) is still one of the most common reasons for hospitalization in developed countries with an aging population worldwide. A substantial proportion of patients with acute HF show significant renal dysfunction. Treatment of congestive HF itself is limited by worsening renal function, despite persistent volume overload. This connection between HF and renal dysfunction has been termed the cardiorenal syndrome and has made treatment of patients with stable and unstable HF difficult. Blocking the tubuloglomerular feedback mechanism with adenosine A1 receptor antagonists such as SLV320 seems to improve diuresis and sodium excretion without compromising glomerular filtration rate in patients with HF. This study confirmed existing clinical data in patients with chronic HF, however, by use of, for the first time in a hemodynamic chronic HF clinical study, a biomarker for glomerular filtration rate: cystatin C. By using this biomarker, we demonstrated a fast and sustained improvement of GFR after SLV320 infusion. Thus, cystatin C might be a biomarker even suitable to describe acute renal effect of new drugs in clinical research. This study also analyzed, for the first time, direct cardiac effects of A1 adenosine receptor antagonists. We demonstrated that SLV320 has no direct effects on heart rate, blood pressure, pulmonary capillary wedge pressure, mean pulmonary arterial pressure, systemic vascular resistance, right atrial pressure, and cardiac output. We concluded that SLV320 infusion shows no immediate effects on cardiac hemodynamics. SLV320 might improve glomerular filtration rate while simultaneously promoting natriuresis and diuresis. It remains to be demonstrated that these immediate renal effects translate into clinical benefits on the long run.
Conclusions: SLV320 infusion shows no immediate effects on cardiac hemodynamics. SLV320 might improve glomerular filtration rate while simultaneously promoting natriuresis and diuresis. 13
Prevalence and Prognostic Significance of Elevated ␥-Glutamyltransferase in Chronic Heart Failure
Summary: Serum ␥-glutamyltransferase (GGT) analysis is traditionally considered to be an index of hepatobiliary dysfunction and alcohol abuse. Recently, large epidemiological studies have revealed an association between GGT and incident cardiovascular diseases and its potential to predict disease mortality. In addition, elevation of GGT levels in patients with heart failure was suggested in previous studies. Therefore, we tested the hypothesis that GGT levels are associated with severity of heart failure and adverse prognosis in 1033 consecutive patients with chronic heart failure. We show that prevalence of elevated GGT levels is high in chronic heart failure. Furthermore, GGT reliably predicted disease severity and 5-year event rates in both men and women irrespective of established demographic, clinical, or biochemical risk factors, such as aminoterminal pro-B-type natriuretic peptide. The predictive value of elevated GGT levels was clearly greater in patients with mild to modest symptoms and in patients younger than 70 years. Although these findings remain to be validated in future studies, we strongly believe this inexpensive and easily accessible biomarker will be useful as a supplementary biomarker in chronic heart failure.
Conclusions: Prevalence of elevated GGT is high in patients with chronic heart failure. The GGT levels are associated with disease severity. Increased GGT is an independent predictor of death or heart transplantation. GGT may provide additional prognostic information, especially in patients with mild heart failure. 14
Nocturnal Rostral Fluid Shift: A Unifying Concept for the Pathogenesis of Obstructive and Central Sleep Apnea in Men With Heart Failure
Summary: Obstructive and central sleep apnea (OSA and CSA, respectively) occur commonly in patients with heart failure (HF) and are associated with increased mortality. However, causes of these breathing disorders are not well established in the setting of HF but are thought to arise through different mechanisms: OSA through obesity and anatomic narrowing of the pharynx, and CSA through hypocapnia and increased chemoreceptor sensitivity. However, the observation that OSA and CSA can occur simultaneously in HF patients suggested a common pathophysiological mechanism linking these 2 disorders. Because HF is a fluid-retaining state, we hypothesized that overnight displacement of fluid from the legs into the neck might lead to OSA by narrowing the pharynx and to CSA if fluid shifted into the lungs and caused stimulation of vagal receptors that stimulate hyperventilation and lower pCO 2 . We confirmed these hypotheses in HF patients by demonstrating that the degree of overnight shift of fluid from the legs was related to the severity of sleep apnea as determined by the apnea-hypopnea index. In the case of OSA, this was through a concomitant increase in neck circumference. In the case of CSA, this was through an inverse relationship with pCO 2 , presumably because of fluid movement into the lungs. Thus, a common mechanism linking OSA and CSA in HF patients is fluid retention and overnight rostral fluid displacement. These novel findings suggest that manipulation of fluid status may be a novel means by which to treat OSA and CSA in HF patients.
Conclusions:
Our findings suggest that nocturnal rostral fluid shift is a unifying concept contributing to the pathogenesis of both OSA and central sleep apnea in patients with heart failure. 15
Engraftment, Differentiation, and Functional Benefits of Autologous Cardiosphere-Derived Cells in Porcine Ischemic Cardiomyopathy
Summary: Every year, more than 1 million Americans suffer a myocardial infarction; nearly one third will go on to develop heart failure. This burden of ischemic cardiomyopathy has driven interest in stem cell therapy, in the hope that damaged myocardium might be repaired. Cardiosphere-derived cells (CDCs) are cardiac-derived stem cells and supporting cells that can be isolated from minimally invasive percutaneous endomyocardial biopsies and grown to large numbers (millions) in a few weeks. CDCs have the advantage of being preprogrammed to differentiate into cardiac and vascular lineages, but not into cell types that are alien to the heart. In mice, human CDCs delivered postinfarction engraft, reduce infarct size, and preserve left ventricular function compared with placebo. To further translate these findings, we studied CDCs in a porcine model of anterior myocardial infarction and resultant ischemic cardiomyopathy. We found that endomyocardial biopsy after myocardial infarction is safe, and CDC isolation from these biopsies is highly successful. After optimization of the delivery solution, autologous CDCs may be safely delivered via intracoronary infusion at doses that result in engraftment and formation of new cardiac myocytes and vascular cells. As compared with placebo infusion, animals receiving CDCs had decreased infarct size, less postinfarct ventricular remodeling, and improved hemodynamic function. No neoplastic or proarrhythmic side effects were observed. Together, these results indicate that CDCs are a novel, safe, and potentially effective therapy for ischemic cardiomyopathy. Recently, the National Institutes of Health-sponsored phase I CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction trial was initiated to study intracoronary delivery of autologous CDCs in patients with mild-to-moderate ischemic cardiomyopathy.
Conclusions: Intracoronary delivery of CDCs in a preclinical model of postinfarct left ventricular dysfunction results in formation of new cardiac tissue, reduces relative infarct size, attenuates adverse remodeling, and improves hemodynamics. The evidence of efficacy without obvious safety concerns at 8 weeks of follow-up motivates human studies in patients after myocardial infarction and in chronic ischemic cardiomyopathy. 16 
Acute Cardiovascular Effects of Apelin in Humans: Potential Role in Patients With Chronic Heart Failure
Summary: Heart failure constitutes a major and growing health burden in developed nations. Despite considerable treatment advances, it has a prognosis worse than that of many cancers and results in severe morbidity with impaired quality of life and recurrent hospitalization. The development of novel treatments for patients with heart failure therefore remains a major research priority. Apelin was recently identified as the endogenous ligand for the novel G protein-coupled receptor APJ. In preclinical models, apelin enhanced myocardial contractility and cardiac output, reduced ventricular preload and afterload, and retarded progression of heart failure. We have recently shown for the first time that apelin is vasoactive in humans, causing reproducible nitric oxide-mediated vasodilatation in the human forearm. In the present series of studies, we demonstrate that systemic apelin infusion in humans increases cardiac output while lowering peripheral vascular resistance. In addition, we demonstrate that apelin is a coronary vasodilator and increases cardiac contractility in humans. Finally, we show that both the local vascular and systemic hemodynamic effects of apelin are preserved in patients with stable chronic heart failure maintained on optimal contemporary pharmacological therapy. We therefore believe that APJ agonism represents an exciting novel therapeutic target in patients with both acute and chronic heart failure.
Conclusions: Acute apelin administration in humans causes peripheral and coronary vasodilatation and increases cardiac output. APJ agonism represents a novel potential therapeutic target for patients with heart failure. 17
T-Type Ca 2؉ Channel Blockade Prevents Sudden Death in Mice With Heart Failure
Summary: Despite recent progress in nonpharmacological therapy, pharmacological interventions for the treatment and prevention of lethal arrhythmias associated with heart failure remain limited. In this study, we used mouse models of ischemic and nonischemic cardiomyopathy to show that T-type Ca 2ϩ channel blockade diminishes arrhythmogenicity and prevents sudden death in heart failure. The dual T-and L-type Ca 2ϩ channel blocker mibefradil was withdrawn from the market because of an unexpected side effect unrelated to the T-type Ca 2ϩ channel blockade: It inhibited cytochrome p450s, thereby causing negative drug-drug interactions. Another dual T-and L-type Ca 2ϩ channel blocker, efonidipine, which we used in this study, has been used in Japan for several years to treat hypertension, and no severe side effects have yet been identified. Although further investigation is necessary, our results suggest that efonidipine and perhaps other T-type Ca 2ϩ channel blockers, especially selective T-type Ca 2ϩ channel blockers such as the R(Ϫ)-isomer efonidipine, may be clinically useful for the prevention of lethal arrhythmias and sudden death in patients with heart failure.
Conclusions: T-type Ca 2ϩ channel blockade reduced arrhythmias in a mouse model of dilated cardiomyopathy by repolarizing the resting membrane potential and improving cardiac autonomic nervous system imbalance. T-type Ca 2ϩ channel blockade also prevented sudden death in mice with myocardial infarction. Our findings suggest T-type Ca 2ϩ channel blockade is a potentially useful approach to preventing sudden death in patients with heart failure. 18
Association of Cystatin C With Left Ventricular Structure and Function: The Dallas Heart Study
Summary: Cystatin C, a novel marker of renal function, has been shown to be a risk factor for heart failure and cardiovascular disease mortality. Whether cystatin C is associated with preclinical cardiac structural abnormalities is unknown. In this study, we evaluated the association of cystatin C with various measures of LV structure and function within the Dallas Heart Study, a young population-based sample. We observed that cystatin C was associated with measures of LV structure including LV mass, wall thickness, and concentricity independent of various markers of renal function. This association was particularly robust in hypertensives and in blacks. Additional evaluation of the mechanistic link between cystatin C and these measures of ventricular structure may provide insight into the pathophysiology of cardiorenal disease. Prospective studies are also warranted to assess if cystatin C is a predictor for the development of cardiac structural abnormalities and adverse outcomes.
Conclusions: Higher levels of cystatin C were associated with increased LV mass and a concentric LV hypertrophy phenotype. These findings were independent of potential confounding variables including standard measurements of renal function, supporting the hypothesis that cystatin C may be useful to identify individuals with preclinical structural heart abnormalities. 19 
Functional Adiponectin Resistance at the Level of the Skeletal Muscle in Mild to Moderate Chronic Heart Failure
Summary: Skeletal muscle dysfunction is an important determinant of exercise intolerance in patients with chronic heart failure (CHF). In addition to structural and functional abnormalities, changes involving mitochondrial bioenergetics explain the energetic deficit that characterizes skeletal muscles of these patients. Recently, insulin resistance has gained attention as a relevant pathophysiological mechanism in CHF. Adiponectin is an insulin-sensitizing cytokine, promoting the uptake and oxidation of glucose and fatty acids at the level of the skeletal muscle. High circulating adiponectin levels infer poor prognosis in patients with CHF. However, the regulation of the local adiponectin system at the level of the skeletal muscle and its metabolic consequences in this population have not been explored previously. In this study, comparison of skeletal muscle biopsies from healthy subjects and patients with CHF showed that in the latter, mRNA expression for adiponectin was significantly increased, whereas it was reduced for the main adiponectin receptor. In addition to these local changes, deactivation of the peroxisome proliferatoractivated receptor-␣/AMP-activated protein kinase pathway and downregulation of several target genes involved in both fatty acid oxidation and glucose metabolism were shown. Taken together, these findings suggest the existence of a functional adiponectin resistance. Hence, increased circulating adiponectin concentrations probably represent a protective mechanism to counteract adiponectin resistance and the compromised energy metabolism. The inverse relationship between exercise parameters and circulating adiponectin in patients with CHF supports the assertion that the more the skeletal muscle metabolism is disturbed, the higher the adiponectin compensatory mechanism is activated.
Conclusions: Despite increased adiponectin expression in the skeletal muscle, patients with CHF are characterized by downregulation of AdipoR1 that is most probably linked to deactivation of the PPAR-␣/AMP-activated protein kinase pathway. These facts suggest functional adiponectin resistance at the level of the skeletal muscle in CHF. 20
Effect of Flow-Triggered Adaptive Servo-Ventilation Compared With Continuous Positive Airway Pressure in Patients With Chronic Heart Failure With Coexisting Obstructive Sleep Apnea and Cheyne-Stokes Respiration
Summary: In patients with chronic heart failure (CHF), the presence of sleep-disordered breathing, including either obstructive sleep apnea or Cheyne-Stokes respiration-central sleep apnea, is associated with a poor prognosis. A large-scale clinical trial showed that continuous positive airway pressure (CPAP) did not improve the prognosis of such patients with CHF, probably because of insufficient sleep-disordered breathing suppression. Recently, it was reported that adaptive servo-ventilation (ASV) can effectively treat sleep-disordered breathing. However, there are no specific data about the efficacy of flow-triggered ASV for cardiac function in patients with CHF with sleep-disordered breathing. The aim of this study was to compare the efficacy of flow-triggered ASV with CPAP in patients with CHF with coexisting obstructive sleep apnea and Cheyne-Stokes respiration-central sleep apnea. Thirty-one patients with CHF, defined as left ventricular ejection fraction Ͻ50% and New York Heart Association class ՆII, with coexisting obstructive sleep apnea and Cheyne-Stokes respiration-central sleep apnea, were randomly assigned to either CPAP or flow-triggered ASV. The suppression of respiratory events, changes in cardiac function, and compliance with the devices during the 3-month study period were compared. Although both devices decreased respiratory events, ASV more effectively suppressed respiratory events (⌬AHI [apneahypopnea index]: Ϫ35.4Ϯ19.5 with ASV, Ϫ23.2Ϯ12.0 with CPAP, PϽ0.05). Compliance was significantly greater with ASV than with CPAP (5.2Ϯ0.9 versus 4.4Ϯ1.1 hour/night, PϽ0.05). The improvements in quality-of-life and LVEF were greater in the ASV group (⌬LVEF: ϩ9.1Ϯ4.7% versus ϩ1.9Ϯ10.9%). These results suggest that patients with coexisting obstructive sleep apnea and Cheyne-Stokes respiration-central sleep apnea may receive greater benefit from treatment with ASV than with CPAP.
Conclusions: These results suggest that patients with coexisting obstructive sleep apnea and Cheyne-Stokes respiration-central sleep apnea may receive greater benefit from treatment with ASV than with CPAP. 21
Endogenous Erythropoietin and Outcome in Heart Failure
Summary: Small-scale studies in patients with heart failure (HF) have suggested that a single measurement of erythropoietin levels has prognostic value. In the present study, we sequentially measured erythropoietin levels in a large cohort of HF patients. We confirmed that elevated erythropoietin levels were independently related to a poor prognosis. Furthermore, patients in whom erythropoietin levels remained high at a second measurement had an even worse prognosis compared with patients with only 1 elevated erythropoietin measurement. Moreover, we showed that anemic HF patients with erythropoietin levels higher than expected, ie, suggesting erythropoietin resistance, have an increased mortality risk. Although erythropoietin might be used in everyday clinical practice as a prognostic marker in HF, we believe that these results may be potentially interesting for additional reasons. First, evaluation of erythropoietin levels in HF may help us better understand the pathophysiology of HF. Second, erythropoiesis-stimulating agents are currently studied as a possible novel therapy in HF; therefore, insight into the natural course of erythropoietin in HF is essential. In this respect, a certain group of patients appear to be erythropoietin resistant, and it may be speculated that this resistance might also be associated with the response to exogenous erythropoietin.
Conclusions: Erythropoietin levels predict mortality in HF patients, and persistently elevated levels have an independent prognostic value. In anemic HF patients, the majority had a low observed/ predicted ratio. However, a higher observed/predicted ratio may be related to an independent increased mortality risk. 22
Rapid Emergency Department Heart Failure Outpatients Trial (REDHOT II): A Randomized Controlled Trial of the Effect of Serial B-Type Natriuretic Peptide Testing on Patient Management
Summary: Brain natriuretic peptide (BNP) has been shown to be helpful in the diagnosis and prognosis of patients with heart failure. The current multicenter randomized clinical trial was designed to determine whether performing serial bedside point-of-care BNP levels would alter management and improve patient outcomes in patients with acute heart failure compared with standard BNP testing. In this study of 447 patients hospitalized for suspected heart failure, we were unable to demonstrate a benefit of serial testing with BNP in terms of hospital length of stay, mortality, or readmission rate. Therefore, we do not recommend routine serial BNP testing in patients with acute heart failure.
Conclusions: In this study of 447 patients hospitalized for suspected heart failure, we were unable to demonstrate a benefit of serial testing with B-type natriuretic peptide in terms of hospital length of stay, mortality, or readmission rate. 23
Socioeconomic Position and Graft Failure in Pediatric Heart Transplant Recipients
Summary: The association of race with graft failure in recipients of heart and other solid organ transplantation has often been attributed to differences in biological (genetic and immunologic) factors. However, race is also a social construct and is associated with socioeconomic (SE) position through differences in income, wealth, and education in racial groups. In this study, we assessed whether patient SE position, based on the SE characteristics of the neighborhood of patient residence, is associated with graft failure in pediatric heart transplant recipients. We used the US Census 2000 database to derive a composite SE score for the block group of residence for 135 patients who underwent their first heart transplant at our institution between 1991 and 2005. We compared the risk of graft failure (death or retransplant) in the lowest tertile SE group (low SE group) to the remaining 2 of 3 patients (controls). Graft failure occurred in 46 transplant recipients (40 deaths, 6 retransplant). Low SE patients had a 140% increase in risk and nonwhite patients a 170% increase in risk of graft failure in univariate analysis. In a multivariable model controlling for diagnosis and pretransplant support, race and low SE position remained significant risk factors for graft failure. Low SE e474
Circulation November 1, 2011 position patients also had a higher incidence of graft rejection. These findings indicate the importance of controlling for SE factors in research relating clinical posttransplant outcomes to biological and genetic differences in different racial groups. Multilevel interventions directed at low SE group patients may improve posttransplant outcomes.
Conclusion: Low SE position may be an independent risk factor for graft failure in pediatric heart transplant recipients. 24
Oxidative Stress Regulates Left Ventricular PDE5 Expression in the Failing Heart
Summary: Congestive heart failure (CHF) is a leading cause of mortality in developed countries that is increasing in prevalence. In the present study, we found that myocardial phosphodiesterase type 5 (PDE5) protein content is increased in patients with end-stage CHF and that this increase is correlated with markers of increased myocardial oxidative stress. Inhibition of PDE5 increases cyclic 3-guanosine monophosphate bioavailability and has been shown to attenuate systolic overload-induced left ventricular (LV) hypertrophy and CHF in animal models. Our finding that either decreasing oxidative stress with a superoxide dismutase mimetic or inducible nitric oxide synthase gene deletion blunted the increase of myocardial PDE5 expression and LV dysfunction in mice subjected to systolic pressure overload implies that increased oxidative stress and inducible nitric oxide synthase expression at least partially contributed to the increased PDE5 expression and contractile dysfunction.
The finding that inhibition of PDE5 with sildenafil reduced myocardial oxidative stress, PDE5 expression, and LV dysfunction indicates a role for the increased PDE5 expression in contributing to the increased oxidative stress and LV dysfunction in the overloaded heart. These data provide the first direct evidence that oxidative stress and inducible nitric oxide synthase can regulate PDE5 expression in cardiac myocytes and suggest that PDE5 inhibition, antioxidant treatment, or inducible nitric oxide synthase inhibition can decrease PDE5 expression in the overloaded heart and might be effective approaches to attenuate systolic overload-induced LV hypertrophy and CHF. This work suggests that further exploration of the use of PDE5 inhibitors or antioxidants in CHF is warranted.
Conclusions: Myocardial oxidative stress increases PDE5 expression in the failing heart. Reducing oxidative stress by treatment with M40401 attenuated cardiomyocyte PDE5 expression. This and selective inhibition of PDE5 protected the heart against pressure overload-induced left ventricular hypertrophy and CHF. 25
Impact of Center Volume on Outcomes of Left Ventricular Assist Device Implantation as Destination Therapy: Analysis of the Thoratec HeartMate Registry, 1998 to 2005
Summary: Between 1998 and 2005, 377 patients underwent implantation of left ventricular assist device as a permanent alternative to heart transplantation or destination therapy (DT) in the United States. The discrepancy between the projected national demand for alternative cardiac replacement therapies, estimated at hundreds of thousands of patients every year, and the actual modest application of this therapy was largely attributable to the continued use of DT as the "end-of-life" treatment. The restricted application of DT to the sickest patients resulted in a large number of accredited hospitals (47 of 68 centers) to perform Յ4 DT implantations. Outcomes of device therapy seemed to substantially improve as centers gained experience. Patients who received Ͼ9th DT implant at a given institution had on average 20% better 1-year survival when compared with those who received the first 4 implants (67% versus 47% 1-year survival). Although we were not able to elucidate which aspects of center experience played the most critical role for the institutional learning curve, it is most likely that better selection of candidates, systemic approach to surgical and postoperative care, and the long-term medical management, have all contributed to these improvements. Multidisciplinary approach to care of patients with end-stage heart failure and future advancements of device design will likely lead to further improvements in the outcomes of the long-term mechanical circulatory support.
Conclusions:
The institutional experience with DT may have a significant impact on outcomes of this therapy. Better selection of candidates, systemic approach to surgical and postoperative care, as well as the long-term medical management most likely all contribute to these improvements. 26
Resolution of Established Cardiac Hypertrophy and Fibrosis and Prevention of Systolic Dysfunction in a Transgenic Rabbit Model of Human Cardiomyopathy Through Thiol-Sensitive Mechanisms
Summary: Hypertrophic cardiomyopathy (HCM) is a genetic disease characterized by primary cardiac hypertrophy. Cardiac hypertrophic and accompanying fibrosis are major determinants of clinical outcomes, including the risk of sudden cardiac death, not only in patients with HCM but also in patients with various cardiovascular diseases. Current pharmacological agents are not known to reverse established cardiac hypertrophy and fibrosis in patients with HCM. We and others have proposed that cardiac hypertrophy and fibrosis in HCM are secondary to activation of various stress-responsive signaling and trophic molecules, including oxidative stressresponsive molecules. Hence, cardiac hypertrophy and fibrosis are potentially reversible. We show in a transgenic rabbit model of human HCM that long-term treatment with N-acetylcysteine (NAC), a precursor of glutathione, the largest intracellular thiol pool against oxidative stress in the body, reverses established cardiac hypertrophy and fibrosis. We show that treatment with NAC also prevents deterioration of cardiac systolic function and reduces susceptibility to arrhythmias. We document the beneficial effects of NAC at molecular, cellular, and whole organ levels and illustrated putative molecular mechanisms. The findings suggest the potential utility of NAC in treatment of patients with HCM, a major cause of sudden cardiac death in the young and an important determinant of morbidity in the elderly. Because cardiac hypertrophy, fibrosis, and systolic dysfunction are common to various cardiovascular diseases, the findings could have broader clinical implications. Clinical studies are needed to determine the potential beneficial effects of NAC in prevention and treatment of HCM and heart failure in humans.
Conclusions:
Treatment with N-acetylcysteine, a safe prodrug against oxidation, reversed established cardiac phenotype in a transgenic rabbit model of human HCM. Because there is no effective pharmacological therapy for HCM and given that hypertrophy, fibrosis, and cardiac dysfunction are common and major predictors of clinical outcomes, the findings could have implications in various cardiovascular disorders. 27
Neuregulin-1␤ Is Associated With Disease Severity and Adverse Outcomes in Chronic Heart Failure
Summary: Neuregulin-1 (NRG-1) is a paracrine growth factor released from cardiac microvascular endothelial cells that acts via the ErbB family of tyrosine kinase receptors to regulate cardiomyocyte differentiation, growth, and stress responsiveness. Alteration of this pathway in animals induces heart failure, whereas peripheral administration of recombinant NRG-1␤ partially restores ventricular function and improves survival in animal models of cardiomyopathy. In humans, the chemotherapeutic agent trastuzumab, which inhibits the ErbB2 receptor, can induce a reversible cardiomyopathy as a toxic side effect, strongly suggesting that NRG-1/ErbB signaling is cardioprotective in the human heart. Here we provide the first study of endogenous circulating NRG-1␤ in human heart failure. We used a
The Editors Most Read in Heart Failure, Part II e475 novel immunoassay to quantify circulating NRG-1␤ levels in 899 subjects in the Penn Heart Failure Study, a large referral cohort of patients with a broad spectrum of primarily systolic failure. We determined that increased levels of NRG-1␤ were independently associated with disease severity and risk of death or cardiac transplantation. Associations were independent of brain natriuretic peptide and were strongest in patients with ischemic heart failure and in patients with New York Heart Association class III/IV symptoms. Moreover, assessment NRG-1␤ and brain natriuretic peptide jointly improved risk stratification beyond assessment of each biomarker individually in these 2 subgroups. With further study, NRG-1␤ may be useful as part of a panel of biomarkers to assess prognosis in chronic heart failure.
Conclusions: Circulating NRG-1␤ is independently associated with heart failure severity and risk of death or cardiac transplantation. These findings support a role for NRG-1/ErbB signaling in human heart failure and identify serum NRG-1␤ as a novel biomarker that may have clinical applications. 28
DITPA (3,5-Diiodothyropropionic Acid), a Thyroid Hormone Analog to Treat Heart Failure: Phase II Trial Veterans Affairs Cooperative Study
Summary: This was a randomized, placebo-controlled, phase II trial designed to evaluate the safety of and provide preliminary data on the potential efficacy of 3,5-diiodothyropropionic acid in patients with stable congestive heart failure. Although the trial was stopped early because of increased side effects at the dose we chose, the data do show beneficial hemodynamic effects of a thyroid hormone analog in the treatment of congestive heart failure. The use of a thyroid hormone analog to treat congestive heart failure is a new and different conceptual approach to the treatment of heart failure because the presumed mechanism of action of the thyroid hormone analog is to alter the molecular composition of the heart and vasculature. If the outcome in patients with congestive heart failure is to be improved, different approaches must be examined that include structural and molecular targets as opposed to attempts to achieve more and more neurohormonal blockade.
Conclusions: DITPA improved some hemodynamic and metabolic parameters, but there was no evidence for symptomatic benefit in congestive heart failure. 29
Hyperuricemia and Incident Heart Failure
Summary: Heart failure is an incurable condition that is responsible for at least 287 000 deaths annually. Heart failure is the most common reason for hospitalization among people on Medicare, and the number of hospitalizations has been increasing over time. We propose that hyperuricemia is a useful biomarker for estimating risk for heart failure and tested this hypothesis using the data from Framingham Offspring Study. We observed that the incidence of heart failure among those with serum uric acid concentrations Ͼ6.3 mg/dL was 6-fold higher than that among participants with serum uric acid Ͻ3.4 mg/dL. The adjusted risk for heart failure was double among those with hyperuricemia. Our findings have implications for early identification of those at risk for heart failure and put forward a new target for intervention.
Conclusions: Hyperuricemia is a novel, independent risk factor for heart failure in a group of young general community dwellers. This has implications for development of preventive strategies for heart failure. 30
An ␣ 2C -Adrenergic Receptor Polymorphism Alters the Norepinephrine-Lowering Effects and Therapeutic Response of the ␤-Blocker Bucindolol in Chronic Heart Failure
Summary: Drugs that have been shown to be effective in a disease population work in only a subset, typically estimated at 30% to 50% of the total. It has long been a dream of those involved in drug development to be able to more accurately define a drug's responsive subpopulation, ideally by a widely available and accurate biomarker. The ␣ 2C -adrenergic receptor regulates norepinephrine (NE) release from adrenergic nerve terminals, including those in the heart. Bucindolol is a novel ␤-adrenergic receptor blocking agent that reduces NE release, the only ␤-blocking agent that does so. This reduction in NE by bucindolol is modulated by ␣ 2C -adrenergic receptors for which there is a relatively common (Ϸ10% of the general population) minor polymorphic allele that leads to a 4 amino acid deletion in the receptor protein, resulting in nearly total loss of function. When this allele is present in either a single (heterozygotes) or double copy, dysregulation of NE release results. This dysregulation leads to a substantial increase in inhibition of NE release of bucindolol. As a result, NE levels precipitously fall to levels below that which can support cardiac function, predisposing the patient to adverse events that cancel the beneficial effects of ␤-blockade. On the other hand, when the major "wild type" allele is present in the homozygous state, bucindolol produces only mild and clinically beneficial degrees of NE lowering. Thus, the use of genetic testing could improve the clinical response to bucindolol, which is a strategy being pursued in the development of this drug.
Conclusions:
In the ␤-Blocker Evaluation of Survival Trial AR polymorphism substudy, the norepinephrine lowering and clinical therapeutic responses to bucindolol were strongly influenced by ␣ 2C receptor genotype. 31
Doppler Echocardiography in Advanced Systolic Heart Failure: A Noninvasive Alternative to Swan-Ganz Catheter
Summary: Assessment of central hemodynamics is an essential component of orthotopic heart transplantation recipient evaluation, and threshold values for selected hemodynamic variables have been identified that predict unfavorable outcomes after transplantation. Swan-Ganz catheterization remains the gold standard for the assessment of central hemodynamics, but it is invasive, not without risks, and not practical for widespread application. In this study, we demonstrated that Doppler echocardiography may offer today a valid alterative to invasive cardiac catheterization for the comprehensive hemodynamic assessment of predominantly stable patients with advanced systolic heart failure and of potential heart transplant recipients. Importantly, the reliable noninvasive measure of pulmonary vascular resistance in stable patients awaiting transplantation in whom the serial assessment of pulmonary vascular resistance is most crucial may obviate the need for routine cardiac catheterization.
Conclusions: Doppler echocardiography may offer a valid alternative to invasive cardiac catheterization for the comprehensive hemodynamic assessment of patients with advanced heart failure, and it may assist in monitoring and optimization of therapy in potential heart transplant recipients. 32
Pressure Overload-Induced Alterations in Fibrillar Collagen Content and Myocardial Diastolic Function: Role of Secreted Protein Acidic and Rich in Cysteine (SPARC) in Post-Synthetic Procollagen Processing
Summary: Chronic heart failure (HF) is associated with and in large part caused by left ventricular remodeling. Although a wide spectrum of types of remodeling occur in patients with chronic HF, studies have often divided chronic HF patients into 2 broad groups based on a clustering of remodeling characteristics: those with HF and a decreased ejection fraction and those with HF and a normal ejection fraction. Patients with HF and a normal ejection fraction have significant abnormalities in left ventricular diastolic function, including increased diastolic pressures, abnormal relaxation and filling, and increased diastolic stiffness. It is for this reason that e476 Circulation November 1, 2011 many, if not most, patients with HF and a normal ejection fraction are said to have diastolic HF. Defining the underlying pathophysiological mechanisms that cause these changes in diastolic function has remained a challenge. The present study used a murine model of pressure overload that resulted in concentric remodeling and diastolic dysfunction, findings similar to those in patients with HF and a normal ejection fraction, to examine the pathophysiological role of increased extracellular matrix fibrillar collagen. Using transgenic technology, the present study examined the role of secreted protein acidic and rich in cysteine (SPARC) in post-synthetic procollagen processing and pressure overload-induced changes in extracellular matrix fibrillar collagen and diastolic dysfunction. Data from the present study support the conclusion that SPARCmediated post-synthetic procollagen processing is one fundamental mechanism by which chronic pressure overload increases myocardial fibrillar collagen content and contributes to the development of diastolic dysfunction. The regulation of SPARC and post-synthetic procollagen processing may provide important mechanism-based targets for the development of novel therapies for patients with chronic HF.
Conclusions:
The absence of SPARC reduced pressure overloadinduced alterations in extracellular matrix fibrillar collagen and diastolic function. These data support the hypothesis that SPARC plays a key role in post-synthetic procollagen processing and the development of mature cross-linked collagen fibrils in normal and pressure-overloaded myocardium. 33
Characteristics and Clinical Significance of Late Gadolinium Enhancement by Contrast-Enhanced Magnetic Resonance Imaging in Patients With Hypertrophic Cardiomyopathy
Summary: Myocardial late gadolinium enhancement (LGE) on contrast-enhanced MRI of patients with hypertrophic cardiomyopathy has been suggested to represent intramyocardial fibrosis. We explored the relation between LGE among 424 patients with hypertrophic cardiomyopathy and their genetic testing status, presence of severe symptoms, ventricular arrhythmias, or occurrence of sudden cardiac death. Two hundred thirty-nine patients (56%) had LGE on contrast-enhanced MRI, ranging from 0.4% to 65% of the left ventricle. Gene-positive patients were more likely to have LGE. The frequencies of New York Heart Association class Ն3 dyspnea and angina class Ն3 were similar in patients with and without LGE.
LGE-positive patients were more likely to have episodes of nonsustained ventricular tachycardia and higher frequency of ventricular extrasystoles/24 hours. During a mean follow-up of almost 4 years, sudden cardiac death occurred in 4 patients, and additional 4 patients received appropriate defibrillator discharges. All 8 patients were LGE positive. The association of LGE with events remained significant after controlling for other risk factors. We concluded that in patients with hypertrophic cardiomyopathy, presence of LGE on contrast-enhanced MRI was common, and more prevalent among gene-positive patients.
LGE was not associated with severe symptoms, but LGE was strongly associated with surrogates of arrhythmia and remained a significant associate of subsequent sudden cardiac death and/or implantation of cardioverter defibrillator discharge. If replicated, LGE may be considered an important risk factor for sudden death in patients with hypertrophic cardiomyopathy.
Conclusions:
In patients with hypertrophic cardiomyopathy, presence of LGE on CE-MRI was common and more prevalent among gene-positive patients.
LGE was not associated with severe symptoms. However, LGE was strongly associated with surrogates of arrhythmia and remained a significant associate of subsequent sudden cardiac death and/or implanted cardioverter defibrillator discharge after controlling for other variables. If replicated, LGE may be considered an important risk factor for sudden death in patients with hypertrophic cardiomyopathy. 34
Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
Summary: Heart failure represents an enormous medical and societal burden. In the past, hypertension and valvular heart disease were the primary causes of heart failure in the United States. In recent years, however, coronary artery disease has emerged as the major cause of heart failure (ischemic cardiomyopathy). Notably, the degree of left ventricular dysfunction in ischemic cardiomyopathy is often out of proportion to the amount of overtly infarcted heart tissue. This suggests that ischemia per se can cause cardiac dysfunction. The Prolyl Hydroxylase Domain-Containing Protein (PHD) prolyl hydroxylases translate changes in oxygen bioavailability into changes in the abundance of the hypoxia-inducible factor transcriptional factor, a master regulator of cellular response to hypoxia. Under low oxygen conditions, such as occurs during ischemia, PHD function is impaired and hypoxia-inducible factor becomes active. Here, we show that genetically ablating PHD activity in the hearts of mice causes ultrastructural, histological, and functional changes reminiscent of ischemic cardiomyopathy. We show that long-term expression of a constitutively active hypoxia-inducible factor variant also leads to cardiomyopathy. Additionally, we document hypoxia-inducible factor upregulation in a murine chronic myocardial ischemia model and in autopsy samples from patients with ischemic cardiomyopathy. Collectively, our data suggest that long-term PHD inactivation and subsequent long-term hypoxiainducible factor activation contribute to the pathogenesis of ischemic cardiomyopathy.
Conclusion: Sustained loss of PHD activity and subsequent hypoxia-inducible factor activation, as would occur in the setting of chronic ischemia, are sufficient to account for many of the changes in the hearts of individuals with chronic coronary artery disease. 35
Uric Acid-Lowering Treatment With Benzbromarone in Patients With Heart Failure: A Double-Blind Placebo-Controlled Crossover Preliminary Study
Summary: This study addresses the ongoing and undecided discussion on the role of increased uric acid (UA) levels in chronic heart failure pathophysiology: Although hyperuricemia has been proven to predict morbidity and mortality in chronic heart failure, it is still not clear whether UA itself is actively involved in these processes or it is a mere marker of upregulated xanthine oxidase (XO) activity. Several previous studies using the XO inhibitor allopurinol showed beneficial effects on a range of surrogate markers in chronic heart failure. However, this approach is unsuitable to distinguish between the effects of increased UA levels per se and high XO activity (a powerful source of oxygen radial production). In this study, this question is addressed using a different therapeutic approach. UA levels were lowered using the uricosuric drug benzbromarone without affecting XO activity. No effect of UA lowering alone on brain natriuretic peptide, atrial natriuretic peptide, clinical, and echocardiographic variables has been observed in this study. These data provide novel evidence in support of upregulated XO activity rather than hyperuricemia per se as the underlying pathophysiologic principle in the context. These data add significant information to the ongoing discussion about hyperuricemia in chronic heart failure.
Conclusions:
These results show that UA lowering without XO inhibition may not have an effect on hemodynamic impairment in CHF pathophysiology. To the extent that these data are correct, this finding suggests that upregulated XO activity rather than UA itself is actively involved in hemodynamic impairment in CHF. 36
Effect of Peri-Infarct Pacing Early After Myocardial Infarction: Results of the Prevention of Myocardial Enlargement and Dilatation Post Myocardial Infarction Study
Summary: Postmyocardial infarction, left ventricular dilation, and heart failure are major determinants of poor outcomes. During the early postinfarct phase (Ͻ1 month) in addition to timely revascularization, arrhythmia monitoring, antiplatelet and antilipid therapies, and neurohormonal modification, peri-infarct left ventricular pacing has been proposed as a method of attenuating the natural history of progression to heart failure. Animal studies and a preliminary clinical evaluation suggest potential benefit. In this randomized, multicenter pilot study, however, we found no clear salutary impact on left ventricular dilation with peri-infarct pacing at 12 months. Nonetheless, the therapy appeared safe, and there was a benefit noted in regional wall motion abnormalities. At this point, therefore, to further develop this line of therapy, a closer analysis of the data and refinement of the patient population, implantation technique, duration of follow-up, and end point are needed.
Conclusions: Chronic pacing in the infarct region did not alter the primary end point of LV remodeling over 1 year. 37
Inhibition of Protein Kinase C-␤ by Ruboxistaurin Preserves Cardiac Function and Reduces Extracellular Matrix Production in Diabetic Cardiomyopathy
Summary: Diabetes mellitus has reached epidemic proportions and will be accompanied by a vast increase in its long-term complications. Despite improved medical care and the use of agents that block the renin-angiotensin-aldosterone and ß-adrenergic systems, mortality remains high. More recently, the syndrome of heart failure with preserved ejection fraction has also been identified and found to have mortality rates approaching that of systolic heart failure. However, unlike the latter, no therapies for heart failure with preserved ejection fraction have been shown to reduce morbidity and mortality, so novel therapeutic targets are being actively explored. One such target is protein kinase C, the ␤-isoform of which is preferentially activated by hyperglycaemia and is upregulated in both human heart failure and in animal models. In the present study, using a hemodynamically validated model of diabetes-induced heart failure with preserved ejection fraction, we demonstrated activation of the protein kinase C ␤-isoform, which was associated with abnormal active and passive relaxation, along with the structural and molecular substrates for abnormal lusitropy. Inhibition of this isoform with ruboxistaurin normalized diastolic function and improved cardiac structure. In the light of recent clinical trials demonstrating safety of ruboxistaurin in diabetic retinal and kidney disease, inhibition of protein kinase C-␤ with ruboxistaurin may represent a novel therapeutic strategy in the treatment of diabetic subjects with heart failure and preserved ejection fraction.
Conclusions: PKC-␤ inhibition attenuated diastolic dysfunction, myocyte hypertrophy, and collagen deposition and preserved cardiac contractility. PKC-␤ inhibition may represent a novel therapeutic strategy for the prevention of diabetes-associated cardiac dysfunction. 38
Multimarker Approach for the Prediction of Heart Failure Incidence in the Community
Summary: Several biological pathways have been individually implicated in left ventricular remodeling and/or heart failure (HF) development, but it is unclear whether biomarkers reflecting these pathways aid in the prediction and stratification of HF risk beyond standard risk factors. In a community-based sample, we prospectively related a panel of circulating biomarkers representing distinct biological pathways, viz, aldosterone-to-renin ratio (renin-angiotensin-aldosterone axis), C-reactive protein (inflammation), plasminogen activator inhibitor-1 (fibrinolysis), B-type natriuretic peptide (natriuretic peptide system), homocysteine (oxidative stress), and the urine albumin-to-creatinine ratio (endothelial function) to the risk of developing new-onset HF. We used a multimarker approach that permitted a comparison of the biomarkers in relation to their contributions to HF risk while limiting multiple testing. We also related a biomarker score (based on biomarkers associated with HF) to HF risk. After adjustment for conventional HF risk factors, B-type natriuretic peptide and urine albumin-to-creatinine ratio emerged as key HF risk predictors. When B-type natriuretic peptide and urine albumin-to-creatinine ratio were modeled as a biomarker score, we observed a striking 10-fold increase in HF incidence across tertiles of biomarker score. Biomarkers provided incremental information over clinical risk factors for predicting HF as assessed by significant improvements in c statistic and net reclassification. The predictive ability of biomarkers was maintained in subgroups with normal left ventricular function, those with renal function, and those without intervening ischemic events. Our findings are consistent with the notion that activation of the natriuretic peptide system and the presence of endothelial dysfunction antedate and predict HF.
Conclusion: Using a multimarker strategy, we identified B-type natriuretic peptide and urinary albumin-to-creatinine ratio as key risk factors for new-onset HF with incremental predictive utility over standard risk factors. 39
Mineralocorticoid Accelerates Transition to Heart Failure With Preserved Ejection Fraction Via "Nongenomic Effects"
Summary: A wealth of data from human systolic heart failure and experimental models of hypertension and heart failure suggests that mineralocorticoid receptor antagonists reduce mortality and attenuate hypertrophy, fibrosis, and diastolic dysfunction. These data have led to the ongoing multicenter randomized Trial of Aldosterone Antagonist Therapy in Adults With Preserved Ejection Fraction Congestive Heart Failure (TOPCAT). Although aldosterone levels are elevated in heart failure with preserved ejection fraction, whether aldosterone itself causes adverse cardiac remodeling, which could promote the transition from hypertensive heart disease to overt heart failure with preserved ejection fraction, is controversial. In this study, we show that oxidative stress is induced in the hypertensive heart and sensitizes the heart to exogenous mineralocorticoids. In normal mice, exogenous mineralocorticoid had little effect on cardiac structure or function. Mice with pressure-overload hypertrophy had increased myocardial oxidative stress, and in these mice, exogenous mineralocorticoid accentuated hypertrophy, fibrosis, and diastolic dysfunction, suggesting an interaction between excess mineralocorticoid (inappropriate for salt status) and oxidative stress. Interestingly, this effect was observed without evidence of classic mineralocorticoid receptor-mediated gene transcription in the heart ("nongenomic" effects) and independently of changes in the magnitude of pressure overload. These results suggest that aldosterone excess may promote the transition from compensated hypertensive heart disease to heart failure with preserved ejection fraction via nongenomic effects or alternatively through effects on noncardiac cells. Because the nongenomic effects of aldosterone are exerted both via the mineralocorticoid receptor and independent from the mineralocorticoid receptor, development of novel antagonists that target both genomic and nongenomic effects may have benefit beyond mineralocorticoid receptor antagonists.
Conclusions: Pressure-overload hypertrophy sensitizes the heart to mineralocorticoid excess, which promotes the transition to heart failure with preserved ejection fraction independently of classic mineralocorticoid receptor-dependent gene transcription. 40
Exercise Hemodynamics Enhance Diagnosis of Early Heart Failure With Preserved Ejection Fraction
Summary: Exertional dyspnea is a common complaint that may be due to cardiac or noncardiac etiologies. When the ejection fraction is depressed in a patient with exertional dyspnea, the diagnosis of heart failure typically is made. However, in patients with normal ejection fraction, it often is challenging to determine whether symptoms are due to heart failure with preserved ejection fraction (HFpEF) or noncardiac dyspnea, particularly when patients appear euvolemic. Clinical indicators of volume overload, such as examination findings, echocardiography, and brain natriuretic peptide levels, are commonly used to distinguish these groups, but it remains unknown whether the absence of volume overload as detected by these resting markers effectively rules out HFpEF. In this study, we demonstrate that in patients with "early" stage HFpEF, hemodynamic evidence of volume overload and diastolic dysfunction may be present only during the stress of exercise, and as such, the diagnosis of HFpEF may only be made by assessing hemodynamic responses during exercise. The increase in pulmonary wedge pressure with leg raise and submaximal exercise along with the increase in pulmonary artery systolic pressure with peak exercise each identified HFpEF with greater accuracy compared to conventional testing used to diagnose heart failure. These results show that the diagnosis of HFpEF may be missed if one relies exclusively on measures of ventricular function and filling pressures obtained at rest. Invasive exercise hemodynamics allow for more accurate and specific diagnosis of early HFpEF among patients complaining of exertional dyspnea.
Conclusions: Euvolemic patients with exertional dyspnea, normal brain natriuretic peptide, and normal cardiac filling pressures at rest may have markedly abnormal hemodynamic responses during exercise, suggesting that chronic symptoms are related to heart failure. Earlier and more accurate diagnosis using exercise hemodynamics may allow better targeting of interventions to treat and prevent HFpEF progression. 41
Cardiac Microvascular Pathology in Fabry Disease: Evaluation of Endomyocardial Biopsies Before and After Enzyme Replacement Therapy
Summary: Among the many differential diagnoses for ischemic heart disease is one on the lower end of the list: cardiac involvement by Fabry disease, a rare lysosomal disorder resulting from a genetic deficiency of ␣-galactosidase A. This deficiency leads to accumulation of globotriaosylceramide within vascular endothelial cells and cardiomyocytes, resulting in angina, myocardial infarction, and left ventricular hypertrophy, thus mimicking more common diagnoses such as hyperlipidemia and hypertrophic cardiomyopathy. The present study uses endomyocardial biopsies to examine the effectiveness of a new enzyme replacement therapy for Fabry disease on its ability to clear globotriaosylceramide from the cardiac microcirculation. In clinical cases in which a diagnostic cardiac biopsy is sought, it is important that Fabry disease be considered in the differential diagnoses of both the ordering physician and the examining pathologist, so that the biopsy specimen can be optimally fixed and processed for light and electron microscopy to enable confirmation of all possible diagnoses. With the current availability of enzyme replacement therapy for Fabry disease, a correct diagnosis will ensure that patients are treated in a timely manner to alleviate symptoms and to prevent further disease progression.
Conclusions:
The findings suggest that long-term treatment with recombinant human ␣-galactosidase A may halt the progression of vascular pathology and prevent the clinical manifestations of atherosclerotic disease. This histopathologic study should be a useful guide for clinicians and pathologists who diagnose and follow Fabry patients. 42
Pulse Wave Analysis of the Aortic Pressure Waveform in Severe Left Ventricular Systolic Dysfunction
Summary: The effect of moderate left ventricular systolic dysfunction on ventricular/vascular coupling and the aortic pressure waveform has been well described, but the effect of severe left ventricular systolic dysfunction has not. This research shows that severe left ventricular systolic dysfunction causes measurable changes in the aortic pressure waveform, as determined using noninvasive, highfidelity tonometry of the radial artery and a mathematical transfer function. Standardization of aortic pressure waveform findings in left ventricular systolic dysfunction patients may allow for the clinical use of radial artery pulse wave analysis to noninvasively determine the severity of dysfunction and aid in logical therapy.
Conclusions: Severe left ventricular systolic dysfunction causes measurable changes in the AoPW. Standardization of AoPW findings in left ventricular systolic dysfunction patients may allow for the clinical use of radial artery pulse wave analysis to noninvasively determine the severity of dysfunction and aid in logical therapy. 43
Genetic and Pharmacological Hydrogen Sulfide Therapy Attenuates Ischemia-Induced Heart Failure in Mice
Summary: Heart failure continues to be a major health problem as evidenced by a rise in the number of hospitalizations for heart failure, the number of deaths attributed to heart failure, and the ever-increasing costs associated with care. Therapeutic strategies designed to coincide with the standard means of care are, therefore, needed to combat the development and progression of heart failure. Hydrogen sulfide (H 2 S) is an endogenous gaseous signaling molecule with a diverse physiological profile that has recently been shown to be cardioprotective in various models of cardiac injury. In the present study, we found that either the modulation of endogenous H 2 S production or direct pharmacological H 2 S administration significantly reduced mortality and attenuated the severity of ischemiainduced heart failure in mice. Importantly, the present study demonstrates that although a single administration of H 2 S at the time of reperfusion is beneficial in attenuating infarct size, this alone is not sufficient to improve cardiac function significantly. On the other hand, daily H 2 S therapy for the first 7 days of reperfusion or increased endogenous H 2 S production provided significant improvements in cardiac function, suggesting that multiple therapeutic interventions are paramount for improvements in outcome. Together, these findings further support the emerging concept that H 2 S therapy may be of clinical importance in the treatment of cardiovascular disease and may have a practical clinical use after myocardial infarction to reduce the morbidity and mortality associated with ischemia-induced heart failure.
Conclusions:
The results of the present study suggest that either the administration of exogenous H 2 S or the modulation of endogenous H 2 S production may be of therapeutic benefit in the treatment of ischemia-induced heart failure. 44
The Impact of Donor-Recipient Sex Matching on Survival After Orthotopic Heart Transplantation: Analysis of 18 000 Transplants in the Modern Era
Summary: Limited data has suggested that men who receive heart transplantation from female donors may have decreased survival. In addition, it is believed that women receiving heart transplantation may have lower overall survival irrespective of donor sex. Our study aimed to comprehensively address outcomes associated with donor and recipient sex in heart transplantation using a multi-institutional sample from the United Network for Organ Sharing database. We
The Editors Most Read in Heart Failure, Part II e479 present the outcomes of Ͼ18 000 heart transplantation patients in the modern era and show that male recipients derive a substantial benefit from receiving their heart from a male donor. For females, however, donor sex does not seem to influence mortality. It is noteworthy that overall, women had lower survival than men irrespective of donor sex (3.6% lower at 5 years). The clinical relevance of the study lies primarily in the data surrounding the male recipients. Men should receive hearts from male donors whenever possible because of the substantial mortality benefit with sex matching. In addition, more data regarding how donor and recipient sex influence outcomes in heart transplantation is needed.
Conclusions:
The United Network for Organ Sharing data set has provided a large sample examining donor recipient sex pairing in orthotopic heart transplantation. Men receiving organs for same sex donors have significantly improved short-and long-term survival.
No survival advantage was seen for women with same sex donors. 45
Leptin Signaling in the Failing and Mechanically Unloaded Human Heart
Summary: The obesity paradox refers to an increase risk of developing hypertension, coronary artery disease, and heart failure with increasing body mass index but paradoxically overweight and obese patients with these cardiovascular diagnoses demonstrate more favorable short-and long-term prognoses versus patients with a more normal body mass index. A key advance in our understanding of obesity was the discovery of leptin, a circulating, predominantly fat-derived cytokine, which regulates metabolism and limits appetite through centrally mediated pathways. As more fat accumulates, more leptin is produced. However, a condition of "central leptin resistance" may develop in the presence of chronically increased circulating leptin, in which leptin fails to suppress appetite, setting the stage for clinical obesity. Aside from obesity, circulating leptin is increased independent of body mass index after myocardial infarction and in heart failure. In this study, we examined cardiac leptin production and signaling in failing and mechanically unloaded human hearts from overweight (body mass indexϭ26 kg/m 2 ) but not obese patients. Relative to nonfailing hearts, failing cardiac tissue demonstrated increased cardiac leptin production and signaling through its receptor, as well as activation of cardioprotective signal transducer and activator of transcription-3 and AMP-activated protein kinase proteins. Mechanical unloading with a ventricular assist device reversed these changes. Taken together, these findings suggest that the hyperleptinemia seen in obesity, cardiac ischemia, and heart failure might contribute to the obesity paradox by mediating the activation of cardioprotective peripheral (ie, cardiac) leptin signaling pathways to improve outcomes in the presence of central leptin resistance.
Conclusions:
These results indicate that the failing human heart increases expression of leptin and its receptor and that mechanical unloading downregulates this increase. Further, a cardioprotective role for leptin in the failing human heart is suggested through the activation of signal transducer and activator of transcription-3 and AMP-activated kinase signaling. 46
Therapeutic Activation of Signal Transducer and Activator of Transcription 3 by Interleukin-11 Ameliorates Cardiac Fibrosis After Myocardial Infarction
Summary: In ischemic heart diseases, myocardial damage is initially induced by reduction of blood supply and is subsequently expanded by cardiac remodeling, leading to heart failure. A therapeutic strategy to limit myocardial remodeling, such as angiotensinconverting enzyme inhibitors and ␤-blockers, improves the survival rate; however, the prognosis of heart failure is still not satisfactory. Cardiac remodeling is positively or negatively regulated by a number of neurohumoral factors and cytokines. Here, we examined whether interleukin (IL)-11, a member of the IL-6 family of cytokines, ameliorates postinfarct remodeling, using a model of myocardial infarction by coronary ligation. Treatment with IL-11 reduced fibrosis after myocardial infarction, with attenuation of myocardial dysfunction. IL-11 decreased the frequency of cardiomyocyte death and increased capillary density. IL-11 treatment resulted in STAT3 activation in cardiomyocytes in vivo. Using conditional knockout mice and cardiac-specific transgenic mice, we demonstrated that activation of STAT3 in cardiomyocytes was necessary and sufficient for IL-11-mediated prevention of cardiac adverse remodeling. These findings suggest that IL-11 treatment may be useful as a therapeutic strategy against the onset of heart failure after myocardial infarction. Because human recombinant IL-11, oprelvekin, is clinically used for thrombocytopenia, with a tolerable level of adverse drug effects providing some proof of its safety, our results suggest that IL-11 treatment is a promising novel cytokine therapy for prevention against heart failure.
Conclusions: IL-11 attenuated cardiac fibrosis after myocardial infarction through STAT3. Activation of the IL-11/glycoprotein 130/ STAT3 axis may be a novel therapeutic strategy against cardiovascular diseases. 47
Renal and Hepatic Function Improve in Advanced Heart Failure Patients During Continuous-Flow Support With the HeartMate II Left Ventricular Assist Device
Summary: The HeartMate II left ventricular assist device (LVAD) is a small continuous-flow device that has been shown to provide effective hemodynamic support and improve quality of life in patients being bridged to cardiac transplantation. However, because of the continuous flow of blood with this device, these patients often have no palpable pulse and a very low pulse pressure, and the subsequent effects of continuous flow on end-organ function are unclear. In patients who underwent placement of the HeartMate II as a bridge to transplantation and who were followed up for 6 months of support with the left ventricular assist device, we demonstrated that both hepatic and renal function in patients with abnormal baseline function improved to normal levels by month 1 to 2 and that they remained normal. Additionally, in patients with normal baseline function, we found that renal and hepatic function remained normal during continuous-flow support. In summary, despite low pulsatility, the HeartMate II continuous-flow left ventricular assist device improved both hepatic and renal function in advanced heart failure patients awaiting transplantation.
Conclusions:
The HeartMate II continuous-flow left ventricular assist device improves renal and hepatic function in advanced heart failure patients who are being bridged to transplantation, without evidence of detrimental effects from reduced pulsatility over a 6-month time period. 48
Juvenile Exposure to Anthracyclines Impairs Cardiac Progenitor Cell Function and Vascularization Resulting in Greater Susceptibility to Stress-Induced Myocardial Injury in Adult Mice
Summary: Anthracyclines such as doxorubicin are effective chemotherapeutic agents used for treatment of many cancers. Unfortunately, their clinical use is limited by the risk of severe cardiotoxicity and heart failure that may not manifest until years later. Anthracyclines are of special concern in pediatric oncology because the youngest children are at the greatest risk of developing late-onset cardiotoxicity. In this study, we present the first evidence that anthracycline exposure in juvenile mice reduces the size of the cardiac progenitor pool, impairs their ability to differentiate into cells of cardiac and vascular lineages, and adversely affects vascular development in the heart. Despite normal development and hemodynamic function as adults, these mice develop rapid heart failure in response to physiological or pathological stress. This animal model recapitulates many of the features of late-onset anthracycline toxicity in humans and explains why younger children, who have more dividing progenitor cells, are more vulnerable. Our findings suggest that anthracycline-mediated effects on the progenitor cells might underlie the reduced ability to accomplish physiological hypertrophy as well as cardiac repair and neovascularization. Injection of stem cell mobilizing factors has been shown to enhance migration of bone marrow cells to the heart and to attenuate acute doxorubicin cardiotoxicity. The therapeutic potential of progenitor cells has been demonstrated in animal models in which successful engraftment of progenitor cells improved left ventricular function after myocardial infarction. If progenitor cells are required for neovascularization accompanying physiological hypertrophy or repair, then stem cell mobilization or replacement may ameliorate late-onset heart failure due to anthracyclines.
Conclusions: Our data suggest that anthracycline treatment impairs vascular development as well as progenitor cell function in the young heart, resulting in an adult heart that is more susceptible to stress. 49
Ca 2؉ /Calmodulin-Dependent Kinase II␦ Causes Heart Failure by Accumulation of p53 in Dilated Cardiomyopathy
Summary: Heart failure is an important cause of morbidity and mortality in many industrial countries, and dilated cardiomyopathy (DCM) is one of its major causes. Molecular genetic studies over the last 2 decades have revealed many mutations of various genes in DCM patients, but the precise mechanisms of how such mutations lead to DCM remain largely unknown partly because of a lack of good animal models of DCM. Here, we established the mouse model of DCM by expressing a mutated cardiac ␣-actin gene, which has been reported in patients with DCM, in the heart. The transgenic mice showed gradual dilatation and dysfunction of the left ventricle, resulting in death by heart failure. These phenotypes of the transgenic mice were quite similar to those of human DCM. The number of apoptotic cardiomyocytes and protein levels of p53 were increased in the hearts of the DCM mice. Overexpression of Bcl-2, an antiapoptotic factor, or downregulation of p53 decreased the number of apoptotic cardiomyocytes and improved cardiac function. The DCM mice showed activation of CaMKII␦. The inhibition of CaMKII␦ prevented the increase in p53 and apoptotic cardiomyocytes and ameliorated cardiac function. These results suggest that CaMKII␦ plays a critical role in the development of heart failure in part by accumulation of p53 and induction of cardiomyocyte apoptosis in the DCM mouse model. The inhibition of CaMKII␦ may become a new therapeutic strategy for DCM patients.
